News Published: June 2008 FDA balks at Myozyme scale-up George Mack Nature Biotechnology 26, 592 (2008) Cite this article ...

Myozyme was first to market in 2006 for infantile-onset Pompe, with Lumizyme reaching the market four years later to treat late-onset Pompe in children aged over eight.

The company made around $1.3 billion in sales of Myozyme (alglucosidase alfa) and Nexviazyme (avalglucosidase alfa) – which are both enzyme replacement therapies (ERTs) – in 2022.

News Published: April 2009 Pharma swept up in biogenerics gold rush Mark Ratner Nature Biotechnology 27, 299–300 (2009) Cite this article ...

€750 million fixed-rate notes, due June 2029, bearing interest at an annual rate of 2.625%. €750 million fixed-rate notes, due June 2032, bearing interest at an annual rate of 3.000%. The notes are ...

Objectives To provide up-to-date information on the use of long-term ventilation (LTV) in the UK paediatric population and to compare the results with data collected 10 and 20 years previously. Design ...

2023 - 22 (9) An Introduction to Analytical Challenges, Approaches, and Applications in Mass Spectrometry-Based Secretomics. January 01, 2023 [ MEDLINE Abstract ] ...